Insensitivity of human prolactin receptors to nonhuman prolactins: Relevance for experimental modeling of prolactin receptor-expressing human cells

Endocrinology

Volumn 150, Issue 4, 2009, Pages 1782-1790

  Utama, Fransiscus E ^a   Tran, Thai H ^a   Ryder, Amy ^a   Lebaron, Matthew J ^a   Parlow, Albert F ^b   Rui, Hallgeir ^a,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN; PROLACTIN RECEPTOR;

ANIMAL CELL; ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; CANCER CELL; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; RECEPTOR SENSITIVITY;

ANIMALS; CELL LINE, TUMOR; HORSES; HUMANS; IMMUNOBLOTTING; MICE; PROLACTIN; PROTEIN BINDING; RATS; RECEPTORS, PROLACTIN; STAT5 TRANSCRIPTION FACTOR;

EID: 63849281305     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1057     Document Type: Article

References (47)

1. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA 1998 Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19:225-268
2. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K 1997 Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 16:6926-6935
3. LeBaron MJ, Ahonen TJ, Nevalainen MT, Rui H 2007 In vivo response-based identification of direct hormone target cell populations using high-density tissue arrays. Endocrinology 148:989-1008
4. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N, Kelly PA 1997 Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 11:167-178
5. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE 1995 Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol 146:695-705
6. Vonderhaar BK 1998 Prolactin: the forgotten hormone of human breast cancer. Pharmacol Ther 79:169-178
7. Goffin V, Touraine P, Culler MD, Kelly PA 2006 Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab 2:571-581
8. Katznelson L, Riskind PN, Saxe VC, Klibanski A 1998 Prolactin pulsatile characteristics in postmenopausal women. J Clin Endocrinol Metab 83:761-764
9. Colao A, Vitale G, Di Sarno A, Spiezia S, Guerra E, Ciccarelli A, Lombardi G 2004 Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab 89:2770-2775
10. Soares MJ 2004 The prolactin and growth hormone families: pregnancy-specific hormones/cytokines at the maternal-fetal interface. Reprod Biol Endocrinol 2:51
11. Biswas R, Vonderhaar BK 1987 Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture. Cancer Res 47:3509-3514
12. Lochnan HA, Buteau H, Richards S, Edery M, Kelly PA 1995 Functional activity of the human prolactin receptor and its ligands. Mol Cell Endocrinol 114:91-99
13. Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, Gonzalez L, Porque PG, Leon J, Martin-Perez J 2004 Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells. Oncogene 23:7378 -7390
14. Shafie SM, Grantham FH 1981 Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst 67:51-56
15. Vonderhaar BK 1989 Estrogens are not required for prolactin induced growth of MCF-7 human breast cancer cells. Cancer Lett 47:105-110
16. Gout PW, Beer CT, Noble RL 1980 Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas. Cancer Res 40:2433-2436
17. Utama FE, Lebaron MJ, Neilson LM, Sultan AS, Parlow AF, Wagner KU, Rui H 2006 Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J Endocrinol 188:589-601
18. Shiu RP 1979 Prolactin receptors in human breast cancer cells in long-term tissue culture. Cancer Res 39:4381-4386
19. Cheng Y, Prusoff WH 1973 Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
20. Strasburger CJ, Binder L, Elberg G, Cohen-Chapnik N, Kohen F, Gertler A 1989 Indication of different lactogen and somatogen binding sites in the human growth hormone molecule as probed with monoclonal antibodies. Mol Cell Endocrinol 67:55-62
21. MacLeod JN, Worsley I, Ray J, Friesen HG, Liebhaber SA, Cooke NE 1991 Human growth hormone-variant is a biologically active somatogen and lactogen. Endocrinology 128:1298-1302
22. Isaksson OG, Eden S, Jansson JO 1985 Mode of action of pituitary growth hormone on target cells. Annu Rev Physiol 47:483-499
23. Faure H, Favier A, Tripier M, Arnaud J 1990 Determination of the major zinc fractions in human serum by ultrafiltration. Biol Trace Elem Res 24:25-37
24. Cunningham BC, Bass S, Fuh G, Wells JA 1990 Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 250:1709 -1712
25. Gout PW, Noble RL, Beer CT 1986 Cultured Nb rat lymphoma cells in endocrine and cancer research. Biochem Cell Biol 64:659 -666
26. Ali S, Pellegrini I, Kelly PA 1991 A prolactin-dependent immune cell line (Nb2) expresses a mutant form of prolactin receptor. J Biol Chem 266:20110-20117
27. Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner KU, Kirken RA, Rui H 2007 Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol 21:2218-2232
28. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT 2008 Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 68:236-248
29. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA 1998 Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 83:667-674
30. Sinha YN 1980 Molecular size variants of prolactin and growth hormone in mouse serum: strain differences and alterations of concentrations by physiological and pharmacological stimuli. Endocrinology 107:1959 -1969
31. Cahill CM, Van der Kolk H, Goode JA, Hayden TJ 1994 Development of homologous radioimmunoassays for equine growth hormone and equine prolactin and their application to the detection of circulating levels of hormone in horse plasma. Reprod Nutr Dev 34:309 -328
32. Roser JF, Chang YS, Papkoff H, Li CH 1984 Development and characterization of a homologous radioimmunoassay for equine prolactin. Proc Soc Exp Biol Med 175:510 -517
33. Le Moli R, Endert E, Fliers E, Mulder T, Prummel MF, Romijn JA, Wiersinga WM 1999 Establishment of reference values for endocrine tests. II: hyperprolactinemia. Neth J Med 55:71-75
34. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE 1999 A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res 5:3583-3593
35. Goffin V, Kinet S, Ferrag F, Binart N, Martial JA, Kelly PA 1996 Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J Biol Chem 271:16573-16579
36. Bernichtein S, Jomain JB, Kelly PA, Goffin V 2003 The N-terminus of human prolactin modulates its biological properties. Mol Cell Endocrinol 208:11-21
37. Bernichtein S, Kayser C, Dillner K, Moulin S, Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA, Goffin V 2003 Development of pure prolactin receptor antagonists. J Biol Chem 278:35988 -35999
38. Bernichtein S, Jeay S, Vaudry R, Kelly PA, Goffin V 2003 New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine 20:177-190
39. Goffin V, Struman I, Mainfroid V, Kinet S, Martial JA 1994 Evidence for a second receptor binding site on human prolactin. J Biol Chem 269:32598 -32606
40. Kinet S, Bernichtein S, Kelly PA, Martial JA, Goffin V 1999 Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites. J Biol Chem 274:26033-26043
41. Jomain JB, Tallet E, Broutin I, Hoos S, van Agthoven J, Ducruix A, Kelly PA, Kragelund BB, England P, Goffin V 2007 Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: x-ray structure of Del1-9-G129R-hPRL. J Biol Chem 282:33118 -33131
42. Keeler C, Dannies PS, Hodsdon ME 2003 The tertiary structure and backbone dynamics of human prolactin. J Mol Biol 328:1105-1121
43. Svensson LA, Bondensgaard K, Norskov-Lauritsen L, Christensen L, Becker P, Andersen MD, Maltesen MJ, Rand KD, Breinholt J 2008 Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor. J Biol Chem 283:19085-19094
44. Teilum K, Hoch JC, Goffin V, Kinet S, Martial JA, Kragelund BB 2005 Solution structure of human prolactin. J Mol Biol 351:810 -823
45. Goffin V, Bernichtein S, Kayser C, Kelly PA 2003 Development of new prolactin analogs acting as pure prolactin receptor antagonists. Pituitary 6:89 -95
46. Lissoni P, Vaghi M, Ardizzoia A, Fumagalli E, Tancini G, Gardani G, Conti A, Maestroni GJ 2001 Efficacy of monochemotherapy with docetaxel (taxo-tere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Neuro Endocrinol Lett 22:27-29
47. Lissoni P, Bucovec R, Malugani F, Ardizzoia A, Villa S, Gardani GS, Vaghi M, Tancini G 2002 A clinical study of taxotere versus taxotere plus the antipro-lactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Anticancer Res 22:1131-1134